Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Albireo Pharma Inc (ALBO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 433,163
  • Shares Outstanding, K 12,039
  • Annual Sales, $ 12,740 K
  • Annual Income, $ -46,110 K
  • 60-Month Beta 1.72
  • Price/Sales 35.68
  • Price/Cash Flow N/A
  • Price/Book 4.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.44
  • Number of Estimates 6
  • High Estimate -1.33
  • Low Estimate -1.61
  • Prior Year -1.22
  • Growth Rate Est. (year over year) -18.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.83 +20.61%
on 04/18/19
38.69 -7.00%
on 05/15/19
+5.23 (+17.01%)
since 04/17/19
3-Month
24.99 +43.98%
on 02/21/19
38.69 -7.00%
on 05/15/19
+9.60 (+36.39%)
since 02/15/19
52-Week
19.10 +88.38%
on 12/21/18
38.69 -7.00%
on 05/15/19
+3.16 (+9.63%)
since 05/17/18

Most Recent Stories

More News
Global Constipation Treatment Drug Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

VRX.TO : 30.80 (-3.33%)
IRWD : 11.26 (+13.74%)
SCMP : 18.05 (+0.28%)
ALBO : 35.98 (-4.71%)
PBH : 30.03 (-0.73%)
SGYP : 0.03 (-52.00%)
Albireo Reports First Quarter 2019 Financial Results

Odevixibat Phase 3 PEDFIC 1 PFIC trial continues to enroll as planned

ALBO : 35.98 (-4.71%)
Albireo to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live...

ALBO : 35.98 (-4.71%)
Know the Growth Factor of Constipation Treatment Drug Market Size 2025: AstraZeneca, Bayer AG, Sanofi, Sucampo Pharmaceuticals, Inc., Takeda

VRX.TO : 30.80 (-3.33%)
BAYRY : 15.8300 (-1.06%)
ABT : 75.97 (-0.82%)
IRWD : 11.26 (+13.74%)
SCMP : 18.05 (+0.28%)
ALBO : 35.98 (-4.71%)
PBH : 30.03 (-0.73%)
SGYP : 0.03 (-52.00%)
New Research: Key Drivers of Growth for CBRE Group, Brookfield Asset Management, Zebra Technologies, Trex, Catalyst Biosciences, and Albireo Pharma -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CBRE Group, Inc. (NYSE:CBRE),...

TREX : 58.79 (-3.65%)
ALBO : 35.98 (-4.71%)
CBIO : 8.47 (+0.71%)
CBRE : 47.30 (-0.82%)
BAM : 47.40 (-0.57%)
ZBRA : 179.12 (-5.74%)
Albireo Presents Data on A4250 in Children with Biliary Atresia and Alagille Syndrome at The International Liver Congress 2019

- Reduction in serum bile acids and pruritus observed in both populations -

ALBO : 35.98 (-4.71%)
Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH

- Initiation of Phase 2 clinical trial expected in Q2 2019 -

ALBO : 35.98 (-4.71%)
Albireo to Present at Investor Conferences in April

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will present at the following investor...

ALBO : 35.98 (-4.71%)
Albireo to Present Clinical Data on A4250 in Alagille Syndrome and Biliary Atresia at The International Liver Congress(TM) 2019

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that results from its completed Phase 2 clinical trial...

ALBO : 35.98 (-4.71%)
Albireo Expands Executive Leadership Team with Appointment of Pamela Stephenson as Chief Commercial Officer

-- Significant recent rare disease product launch and access experience --

ALBO : 35.98 (-4.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ALBO with:

Business Summary

Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States....

See More

Key Turning Points

2nd Resistance Point 39.30
1st Resistance Point 37.64
Last Price 35.98
1st Support Level 34.88
2nd Support Level 33.78

See More

52-Week High 38.69
Last Price 35.98
Fibonacci 61.8% 31.21
Fibonacci 50% 28.90
Fibonacci 38.2% 26.58
52-Week Low 19.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar